James Barter Selected Research

Drug Therapy (Chemotherapy)

1/2023	A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
7/2015	Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James Barter Research Topics

Disease

2	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 01/2007
1	Neoplasms (Cancer) 01/2023
1	Endometrial Neoplasms (Endometrial Cancer) 07/2015
1	Wounds and Injuries (Trauma) 08/2003
1	Infections 08/2003
1	Hernia (Hernias) 08/2003
1	Seroma 08/2003
1	Pain (Aches) 08/2003

Drug/Important Bio-Agent (IBA)

2	PlatinumIBA 01/2023 - 07/2015
1	Bevacizumab (Avastin)FDA Link 01/2023
1	ixabepilone (BMS 247550)FDA Link 07/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 07/2015
1	Paclitaxel (Taxol)FDA LinkGeneric 07/2015
1	1-dodecylpyridoxal (PLD)IBA 01/2007
1	liposomal doxorubicin (Doxil)FDA Link 01/2007
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2007

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2023 - 07/2015
1	Aftercare (After-Treatment) 01/2007
1	Sutures (Suture) 08/2003